| Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? R Younes, O Govaere, S Petta, L Miele, D Tiniakos, A Burt, E David, ... Gut 71 (2), 382-390, 2022 | 140 | 2022 |
| Association between PNPLA3 rs738409 C> G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease S Grimaudo, RM Pipitone, G Pennisi, C Celsa, C Cammà, V Di Marco, ... Clinical Gastroenterology and Hepatology 18 (4), 935-944. e3, 2020 | 124 | 2020 |
| Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease R Younes, GP Caviglia, O Govaere, C Rosso, A Armandi, T Sanavia, ... Journal of hepatology 75 (4), 786-794, 2021 | 119 | 2021 |
| Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver … S Petta, G Sebastiani, M Viganò, J Ampuero, VWS Wong, J Boursier, ... Clinical gastroenterology and hepatology 19 (4), 806-815. e5, 2021 | 102 | 2021 |
| Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease O Jamialahmadi, RM Mancina, E Ciociola, F Tavaglione, PK Luukkonen, ... Gastroenterology 160 (5), 1634-1646. e7, 2021 | 95 | 2021 |
| Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis S Pelusi, A Cespiati, R Rametta, G Pennisi, V Mannisto, C Rosso, ... Clinical Gastroenterology and Hepatology 17 (11), 2310-2319. e6, 2019 | 87 | 2019 |
| Antidiabetic drugs in NAFLD: the accomplishment of two goals at once? M Tacelli, C Celsa, B Magro, A Giannetti, G Pennisi, F Spatola, S Petta Pharmaceuticals 11 (4), 121, 2018 | 61 | 2018 |
| The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: screening issue and future perspectives G Pennisi, C Celsa, A Giammanco, F Spatola, S Petta International journal of molecular sciences 20 (22), 5613, 2019 | 47 | 2019 |
| Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta … FE Mózes, JA Lee, Y Vali, O Alzoubi, K Staufer, M Trauner, R Paternostro, ... The Lancet Gastroenterology & Hepatology 8 (8), 704-713, 2023 | 42 | 2023 |
| MAFLD: A multisystem disease RM Pipitone, C Ciccioli, G Infantino, C La Mantia, S Parisi, A Tulone, ... Therapeutic Advances in Endocrinology and Metabolism 14, 20420188221145549, 2023 | 41 | 2023 |
| Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives G Pennisi, C Celsa, F Spatola, M Dallio, A Federico, S Petta International Journal of Environmental Research and Public Health 16 (22), 4334, 2019 | 34 | 2019 |
| AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD G Pennisi, M Enea, A Pandolfo, C Celsa, M Antonucci, C Ciccioli, ... Clinical Gastroenterology and Hepatology 21 (5), 1293-1302. e5, 2023 | 33 | 2023 |
| PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD S Grimaudo, S Bartesaghi, R Rametta, F Marra, R Margherita Mancina, ... Liver International 41 (2), 321-332, 2021 | 28 | 2021 |
| Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis G Pennisi, M Enea, M Romero‐Gomez, M Viganò, E Bugianesi, ... Alimentary pharmacology & therapeutics 55 (5), 604-615, 2022 | 22 | 2022 |
| Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes G Pennisi, M Enea, V Falco, GP Aithal, N Palaniyappan, Y Yilmaz, ... Hepatology 78 (1), 195-211, 2023 | 21 | 2023 |
| PNPLA3 rs738409 C> G variant predicts fibrosis progression by noninvasive tools in nonalcoholic fatty liver disease G Pennisi, RM Pipitone, C Cammà, V Di Marco, V Di Martino, F Spatola, ... Clinical Gastroenterology and Hepatology 19 (9), 1979-1981, 2021 | 12 | 2021 |
| Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis G Pennisi, C Celsa, M Enea, M Vaccaro, V Di Marco, C Ciccioli, ... Nutrition, Metabolism and Cardiovascular Diseases 32 (10), 2279-2288, 2022 | 11 | 2022 |
| Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD P Dongiovanni, M Meroni, S Petta, M Longo, A Alisi, G Soardo, L Valenti, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2020 | 10 | 2020 |
| Interplay between non‐alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population G Pennisi, V Di Marco, C Buscemi, G Mazzola, C Randazzo, F Spatola, ... Journal of Gastroenterology and Hepatology 36 (9), 2389-2396, 2021 | 9 | 2021 |
| Presence of serum antinuclear antibodies does not impact long-term outcomes in nonalcoholic fatty liver disease R Younes, O Govaere, S Petta, L Miele, D Tiniakos, A Burt, E David, ... Official journal of the American College of Gastroenterology| ACG 115 (8 …, 2020 | 9 | 2020 |
Salvatore PettaRicercatore di Gastroenterologia, Università di PalermoEmail verificata su unipa.it
